Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4288774 | 0.88 | MEN1 (0.70) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4295578 | 0.88 | MEN1 (0.65) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4291809 | 0.87 | MEN1 (0.67) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4298838 | 0.87 | MEN1 (0.69) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL13704096 | 0.86 | MEN1 (0.63) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL13704097 | 0.86 | MEN1 (0.63) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL13704095 | 0.86 | MEN1 (0.63) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4294168 | 0.86 | MEN1 (0.65) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4296385 | 0.85 | MEN1 (0.60) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4288951 | 0.85 | MEN1 (0.66) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | BONFANTI JEAN-FRANCOIS | 2009-09-03 | — | — | US | disclosed |
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | BONFANTI JEAN-FRANCOIS | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | GABRA5, GABRA4, GABRA3 | MEN1 4829/4885KMT2A 1440/4885ALDH1A1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.